Literature DB >> 12491025

Interaction between naltrexone and oral THC in heavy marijuana smokers.

Margaret Haney1, Adam Bisaga, Richard W Foltin.   

Abstract

RATIONALE: Studies in non-human animals suggest that opioid antagonists block the reinforcing effects of cannabinoids.
OBJECTIVE: The present studies in humans investigated how naltrexone modulates (1) the subjective and physiological effects of oral THC in comparison to methadone, (2) the reinforcing effects of oral THC, and (3) plasma levels of oral THC.
METHODS: In study 1, marijuana smokers (n=9) received naltrexone (0, 50 mg) followed 30 min later by THC (0, 15, 30 mg) or methadone (5, 10 mg). Subjective effects, task performance, pupillary diameter, and cardiovascular parameters were measured repeatedly. In study 2a, marijuana smokers (n=23) were randomly assigned to one THC dose condition (0, 15 or 30 mg). One set of color-coded capsules containing THC and active naltrexone (50 mg) was given in one session, while another set of color-coded capsules containing THC and placebo naltrexone was given in another session. In the final three sessions, participants chose which color capsules they would receive. In study 2b, a subset of participants from study 2a (n=7) received naltrexone (0, 50 mg) 30 min prior to oral THC (30 mg) administration, and blood was drawn repeatedly.
RESULTS: Pretreatment with naltrexone significantly increased many of the "positive" subjective effects of oral THC (30 mg) e.g. ratings of Good Drug Effect and Capsule Liking. Naltrexone tended to increase the reinforcing effects of oral THC (30 mg), as indicated by performance in a drug choice test. Naltrexone did not alter plasma THC levels.
CONCLUSIONS: These studies demonstrate that naltrexone increases the subjective effects of oral THC. Thus, oral THC's effects are enhanced rather than antagonized by opioid receptor blockade in heavy marijuana smokers.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12491025     DOI: 10.1007/s00213-002-1279-8

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  35 in total

Review 1.  State of the art treatments for cannabis dependence.

Authors:  Itai Danovitch; David A Gorelick
Journal:  Psychiatr Clin North Am       Date:  2012-04-10

Review 2.  Screening Medications for the Treatment of Cannabis Use Disorder.

Authors:  L V Panlilio; Z Justinova; J M Trigo; B Le Foll
Journal:  Int Rev Neurobiol       Date:  2016-03-10       Impact factor: 3.230

3.  Interactions between μ-opioid receptor agonists and cannabinoid receptor agonists in rhesus monkeys: antinociception, drug discrimination, and drug self-administration.

Authors:  David R Maguire; Wenjuan Yang; Charles P France
Journal:  J Pharmacol Exp Ther       Date:  2013-03-27       Impact factor: 4.030

4.  Open-label pilot study of injectable naltrexone for cannabis dependence.

Authors:  Daniel P Notzon; Meredith A Kelly; C Jean Choi; Martina Pavlicova; Amy L Mahony; Daniel J Brooks; John J Mariani; Frances R Levin
Journal:  Am J Drug Alcohol Abuse       Date:  2018-02-08       Impact factor: 3.829

Review 5.  Are Alcohol Anti-relapsing and Alcohol Withdrawal Drugs Useful in Cannabinoid Users?

Authors:  Patrycja Kleczkowska; Irena Smaga; Małgorzata Filip; Magdalena Bujalska-Zadrozny
Journal:  Neurotox Res       Date:  2016-08-02       Impact factor: 3.911

Review 6.  Preclinical Studies of Cannabinoid Reward, Treatments for Cannabis Use Disorder, and Addiction-Related Effects of Cannabinoid Exposure.

Authors:  Leigh V Panlilio; Zuzana Justinova
Journal:  Neuropsychopharmacology       Date:  2017-08-28       Impact factor: 7.853

7.  Intermittent marijuana use is associated with improved retention in naltrexone treatment for opiate-dependence.

Authors:  Wilfrid Noel Raby; Kenneth M Carpenter; Jami Rothenberg; Adam C Brooks; Huiping Jiang; Maria Sullivan; Adam Bisaga; Sandra Comer; Edward V Nunes
Journal:  Am J Addict       Date:  2009 Jul-Aug

8.  Comparison of subjective, pharmacokinetic, and physiological effects of marijuana smoked as joints and blunts.

Authors:  Ziva D Cooper; Margaret Haney
Journal:  Drug Alcohol Depend       Date:  2009-05-14       Impact factor: 4.492

9.  The opioid antagonist naltrexone reduces the reinforcing effects of Delta 9 tetrahydrocannabinol (THC) in squirrel monkeys.

Authors:  Zuzana Justinova; Gianluigi Tanda; Patrik Munzar; Steven R Goldberg
Journal:  Psychopharmacology (Berl)       Date:  2003-12-11       Impact factor: 4.530

10.  Interactions between Δ(9)-tetrahydrocannabinol and heroin: self-administration in rhesus monkeys.

Authors:  Jun-Xu Li; Wouter Koek; Charles P France
Journal:  Behav Pharmacol       Date:  2012-12       Impact factor: 2.293

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.